Recently, Evaluate Pharma released an analysis report on the trends in the biopharmaceutical industry in 2024. The report mentioned 10 potential key R&D pipelines, including the small molecule drug camizestrant. Camizestrant is a next-generation oral SERD and pure Erα antagonist that has demonstrated anti-cancer activity across a range of preclinical models, including in patients with ER-activating mutations.
Search 
+86 21 5895 0110 
![(R)-3-boc-4-methyl-2,2-dioxo-[1,2,3]oxathiazolidine](https://images.chemenu.com/attachments/products_new/svg/454248-53-4.svg)
amine](https://images.chemenu.com/attachments/products_new/svg/2142634-00-0.svg)
![tert-butyl N-[1-(3-fluoropropyl)azetidin-3-yl]carbamate](https://images.chemenu.com/attachments/products_new/svg/2222845-47-6.svg)